Home › Parkinson's Disease › NCT07599696
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Dominant speakers of North American English * Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP) * Present with changes in their speech/voice Exclusion Criteria: * History of any other speech, language, or neurological concern other than Parkinson/parkinsonism. * Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
About the study
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
What is being tested
- Behavioral speech strategies + speech amplification (behavioral)
Sponsor: Michigan State University · Participants: 100 · Started: Mar 1, 2024
Contact the study team
- Thea Knowles, PhD · Phone: 517-353-6401
Official record on ClinicalTrials.gov — NCT07599696
Locations in the U.S.
| Michigan | Michigan State University, East Lansing |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.